Since their first use as IVT drugs with nAMD patients 15 years ago [79], anti-VEGF therapies have transformed the treatment of macular degeneration and largely replaced less-effective treatments, such as photodynamic therapy [204]. This evidence concerns the gene VEGFA and macular degeneration.